Eli Lilly announced on August 31 that it has entered into a definitive agreement to acquire Merida Biosciences, a U.S. biotech developing therapies for serious autoimmune and allergic diseases, for up to $2.875 billion in cash. The total includes an upfront payment and contingent milestone payments, with closing expected in Q4 2026. Merida is developing […]
Johnson & Johnson announced on August 24 that the FDA approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older previously or currently treated with corticosteroids. It is the first FDA-approved treatment for wAIHA. The approval adds the first treatment option for this rare blood disorder and marks the expansion […]